Orthocell's 'Striate +' recommended for inclusion on the Prostheses List

Latest News

Australian regenerative medicine company Orthocell (ASX:OCC) says its 'Striate +' produce has been recommended to be added to the Australian government's Prostheses List (PL).

“Inclusion on the protheses list is an important step in gaining reimbursement from private insurers for Striate + (previously named CelGro Dental)," said Orthocell managing director Paul Anderson.

"This is a significant milestone for our company that is made possible by our recent Australian TGA approval and clinical data enabling progression towards reimbursement.”

The company said the recommendation for Striate + follows the recent approval of the CelGro collagen medical device for dental bone and tissue regeneration market.